Ken Griffin Humacyte, Inc. Put Options Transaction History

Citadel Advisors LLC

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2025 Aug 14, 2025	SELL	$1.15 - $2.77 $50,599 - $121,880	-44,000 Reduced 30.81%	98,800 $206,000
Q1 2025 May 15, 2025	SELL	$1.71 - $5.18 $258,894 - $784,252	-151,400 Reduced 51.46%	142,800 $244,000
Q4 2024 Feb 14, 2025	SELL	$3.46 - $5.81 $36,676 - $61,585	-10,600 Reduced 3.48%	294,200 $1.49 Million
Q3 2024 Nov 14, 2024	SELL	$5.11 - $9.46 $647,948 - $1.2 Million	-126,800 Reduced 29.38%	304,800 $1.66 Million
Q2 2024 Aug 14, 2024	BUY	$2.87 - $9.1 $967,764 - $3.07 Million	337,200 Added 357.2%	431,600 $2.07 Million
Q1 2024 May 15, 2024	BUY	$2.57 - $4.84 $112,823 - $212,476	43,900 Added 86.93%	94,400 $293,000
Q4 2023 Feb 14, 2024	SELL	$1.99 - $3.12 $24,875 - $39,000	-12,500 Reduced 19.84%	50,500 $143,000
Q3 2023 Nov 14, 2023	BUY	$2.75 - $4.48 $72,325 - $117,824	26,300 Added 71.66%	63,000 $184,000
Q2 2023 Aug 14, 2023	BUY	$2.86 - $4.97 $104,962 - $182,399	36,700 New	36,700 $104,000
Q4 2022 Feb 14, 2023	BUY	$2.02 - $3.62 $30,098 - $53,938	14,900 New	14,900 $31,000

171

54.5M

1.1M

808K

Ticker HUMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,007,000
Market Cap $145M
Description
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.